Abstract 41P
Background
Radiation therapy (RT) for breast cancer (BC) can result in cardiotoxicity including subtle cardiac dysfunction that can occur early after treatment. In 2022, the first European Society of Cardiology (ESC) guidelines in cardio-oncology defined asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), combining both information on left ventricle ejection fraction (LVEF) and global longitudinal strain (GLS) decrease from baseline. This newly defined event has never been studied in a population of BC patients treated with RT. Objective: To evaluate early to mid-term asymptomatic CTRCD occurrence and to analyze the association with radiation-induced cardiac exposure.
Methods
The BACCARAT study included BC patients treated with RT without chemotherapy, aged 40–75 years. Conventional and 2D Speckle tracking echocardiography was performed before RT and 6 and 24 months after RT. Whole heart, left ventricle (LV), coronary arteries doses, and dose-volume parameters were considered to evaluate the impact of cardiac exposure on CTRCD. Classic cardiac risk factors data were also collected.
Results
The study included 72 BC (of 59 left-sided BC) patients with a mean age of 58 years. A total of 32 (44%) patients developed any grade CTRCD during follow up: 22 (31%) developed early, and 14 (19%) developed midterm dysfunction with or without previous dysfunction only in left BC patients. The doses were generally higher among patients with CTRCD rather than non-CTRCD. Significant dose-response relationships were observed between the risk of CTRCD and cardiac exposure, in particular LV (OR for V2 LV dose =1.03 (1.00-1.06) p=0.01 and circumflex CX artery’s mean dose OR = 2.44 (1.26-4.74) p =0.008, D2 OR = 1.79 (1.13-2.85) p=0.01 and V2 OR = 1.02 (1.01-1.04) p=0.01. The results for the CX artery exposure were robust and significant after adjustment for classic cardiac risk factors and analyses according to the CTRCD grade; however, it did not remain significant for LV.
Conclusions
Our study suggests an association between specific cardiac structures and CTRCD, considering classic cardiac risk factors. However, given the limited number of patients, further research is needed.
Clinical trial identification
NCT02605512.
Editorial acknowledgement
Legal entity responsible for the study
Institut de radioprotection et de sûreté nucléaire (IRSN).
Funding
Société française de cardiologie Électricité de France Société française de cardiologie.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - A one-tube multiplex methylation-specific droplet digital PCR assay for identification of ctDNA biomarkers in anal squamous cell carcinoma
Presenter: Karen-Lise Spindler
Session: Poster session 07
95P - Baseline-informed longitudinal monitoring of lung cancer by cell-free DNA methylation profiles
Presenter: Chunxia Su
Session: Poster session 07
96P - A novel strategy for single-nucleus RNA-seq of frozen PAXgene blood: A clinical alternative to single-cell RNA-seq of cryopreserved PBMCs
Presenter: Asaf Rotem
Session: Poster session 07
97P - GENIE-seq: A novel methylation sequencing method for effective and accurate identification of methylation markers from cfDNA
Presenter: Zhaoyun Ding
Session: Poster session 07
98P - Translating cancer tissue methylation to cell-free DNA methylation for minimally invasive cancer detection
Presenter: Edward Post
Session: Poster session 07
99P - Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
Presenter: Kyoungmin Lee
Session: Poster session 07
100P - Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay
Presenter: Lee Schwartzberg
Session: Poster session 07
101P - Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC
Presenter: Fang Wu
Session: Poster session 07